EnWave Reports 2024 Third Quarter Consolidated Interim Financial Results
23 August 2024 - 11:00PM
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the
"Company") today reported the Company’s consolidated
interim financial results for the third quarter ended June 30th,
2024, demonstrating strong improvement over the first and second
quarters this fiscal year.
All values in thousands and denoted in CAD
unless otherwise stated.
- Reported revenue for Q3 2024 of $2,622 compared to $2,486 for
Q3 2023, representing an increase of $136. The increase was related
to a large-scale machine resale with a higher margin and increased
small scale machines sales for the period.
- Reported royalty revenues of $425, representing an increase of
$31 relative to the comparable period in the prior year due to
increased sales and production from current royalty partners.
- Reported an Adjusted EBITDA(1)
(refer to NON-IFRS Financial Measures section below) profit of $85
for Q3 2024, compared to an Adjusted EBITDA(1) loss of $192 in the
same period in the prior year due to the resale of a high margin
large-scale machine and increased royalty revenues.
- Gross margin for the three months ended Q3 2024 was 44%
compared to 29% for the three months ended Q3 2023. The increase in
margin was a result of the resale of the large-scale machine with a
higher margin and increased royalties.
- Reported Selling, General & Administrative (“SG&A”)
costs (including Research & Development (“R&D”)) of $1,364
which increased by $178 from the comparable period in the prior
year due to increased personnel costs, legal fees and increased
sales efforts, including higher attendance at trade shows.
Consolidated Financial
Performance:
($ ‘000s) |
Three months ended June
30, |
|
|
Nine months ended June
30, |
|
|
|
|
|
|
|
|
Change |
|
|
|
|
|
|
|
|
Change |
|
|
|
2024 |
|
|
2023 |
|
|
% |
|
|
|
2024 |
|
|
2023 |
|
|
% |
|
|
|
|
|
|
|
|
|
Revenues |
|
2,622 |
|
|
2,486 |
|
5 |
% |
|
|
|
4,547 |
|
|
9,906 |
|
(54 |
%) |
|
Direct
costs |
|
(1,471 |
) |
|
(1,767 |
) |
(17 |
%) |
|
|
|
(3,330 |
) |
|
(5,894 |
) |
(44 |
%) |
|
Gross margin |
|
1,151 |
|
|
719 |
|
60 |
% |
|
|
|
1,217 |
|
|
4,012 |
|
(70 |
%) |
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
General and administration |
|
664 |
|
|
501 |
|
33 |
% |
|
|
|
1,740 |
|
|
1,753 |
|
(1 |
%) |
|
Sales and marketing |
|
358 |
|
|
277 |
|
29 |
% |
|
|
|
1,149 |
|
|
1,167 |
|
(2 |
%) |
|
Research and development |
|
342 |
|
|
408 |
|
(16 |
%) |
|
|
|
1,127 |
|
|
1,220 |
|
(8 |
%) |
|
|
|
1,364 |
|
|
1,186 |
|
15 |
% |
|
|
|
4,016 |
|
|
4,140 |
|
(3 |
%) |
|
Net loss - continuous
operations |
|
(235 |
) |
|
(918 |
) |
74 |
% |
|
|
|
(2,938 |
) |
|
(974 |
) |
206 |
% |
|
Net loss - discontinued
operations |
|
(32 |
) |
|
(1,031 |
) |
97 |
% |
|
|
|
(35 |
) |
|
(5,703 |
) |
99 |
% |
|
Adjusted EBITDA(1) income
(loss) |
|
85 |
|
|
(192 |
) |
144 |
% |
|
|
|
(1,939 |
) |
|
703 |
|
(376 |
%) |
|
Loss per share: |
|
|
|
|
|
|
|
Continuous operations – basic and diluted |
$ |
0.00 |
|
$ |
(0.01 |
) |
|
|
$ |
(0.02 |
) |
$ |
(0.01 |
) |
|
Discontinued operations – basic and diluted |
$ |
0.00 |
|
$ |
(0.01 |
) |
|
|
$ |
0.00 |
|
$ |
(0.05 |
) |
|
Basic and diluted |
$ |
0.00 |
|
$ |
(0.02 |
) |
|
|
$ |
(0.02 |
) |
$ |
(0.06 |
) |
|
Note: (1) Adjusted EBITDA is a
non-IFRS financial measure. Refer to the Non-IFRS Financial
Measures disclosure below for a reconciliation to the nearest IFRS
equivalent. EnWave’s consolidated interim financial statements and
MD&A are available on SEDAR+ at www.sedarplus.ca and on
the Company’s website www.enwave.net
Key Financial Highlights for the Nine
Months Ended Q3 2024 (expressed in 000’s)
- Royalties for the nine months ending June 30, 2024 were $1,319
compared to $1,085 for the same period ending June 30, 2023, an
increase of $234 or 22%. Royalties grew due to increased partner
product sales and production offset by a decrease in exclusivity
fees.
- Reported revenue for Q3 2024 of $4,547, representing a decrease
of $5,349 relative to the comparable period in the prior year. The
decrease was related to overall fewer machine sales and machines in
fabrication compared to the prior period due to the inherent
volatility in large-scale Radiant Energy Vacuum (“REV™”) machine
orders.
- SG&A costs for the nine months ending June 30, 2024 were
$4,016 compared to $4,140 for the same period ending June 30, 2023,
a decrease of $124, as a result of concerted efforts to maintain
discretionary spending.
- Adjusted EBITDA(1) loss for the
nine months ended Q3 2024 of $1,939, compared to an Adjusted
EBITDA(1) profit of $703 in the same period in the prior year due
to fewer machine sales to absorb fixed overhead costs.
Significant Corporate Accomplishments in
Q3 2024 and Subsequently:
- Signed a
Technology Evaluation and License Option Agreement with a North
American food company led by a renowned chef with multiple Michelin
Stars.
- Signed an
Equipment Purchase Agreement for a 120kW REV® dehydration machine
with an existing royalty partner.
- Signed an
Equipment Purchase Agreement with BranchOut Foods LLC, a current
royalty partner, for a 100kW REV™ dehydration machine to provide
additional drying capacity.
- Signed a
Commercial License Agreement with Bounty Specialty Foods to produce
several product types in the Philippines and sold a 10kW REV™
dehydration machine for product development.
- Signed a
Commercial Licence Agreement with an existing royalty partner to
produce several tropical fruit products in an unspecified Central
American country. An annual six-figure royalty fee will be paid in
exchange for the exclusive rights.
- Subsequent to
the quarter, repurchased a large-scale machine from a cannabis
multi-state operator to expedite the completion of the 120kW REV™
Branchout Foods LLC Equipment Purchase Agreement.
Non-IFRS Financial
Measures:
This news release refers to Adjusted EBITDA which is a non-IFRS
financial measure. We define Adjusted EBITDA as earnings before
deducting amortization and depreciation, stock-based compensation,
foreign exchange gain or loss, finance expense or income, income
tax expense or recovery and non-recurring impairment, restructuring
and severance charges, and discontinued operations. This measure is
not necessarily comparable to similarly titled measures used by
other companies and should not be construed as an alternative to
net income or cash flow from operating activities as determined in
accordance with IFRS. Please refer to the reconciliation between
Adjusted EBITDA and the most comparable IFRS financial measure
reported in the Company’s consolidated interim financial
statements.
|
Three months endedJune 30, |
|
|
Nine months endedJune 30 |
|
($ ‘000s) |
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|
|
|
|
|
|
|
Net loss after income tax |
(267 |
) |
|
(1,949 |
) |
|
(2,973 |
) |
|
(6,677 |
) |
Amortization and depreciation |
299 |
|
|
276 |
|
|
862 |
|
|
841 |
|
Stock-based compensation |
32 |
|
|
103 |
|
|
218 |
|
|
468 |
|
Foreign exchange (gain) loss |
(9 |
) |
|
54 |
|
|
(36 |
) |
|
86 |
|
Finance income |
(42 |
) |
|
(53 |
) |
|
(148 |
) |
|
(132 |
) |
Finance expense |
40 |
|
|
31 |
|
|
103 |
|
|
99 |
|
Non-recurring impairment expense |
- |
|
|
315 |
|
|
- |
|
|
315 |
|
Discontinued operations |
32 |
|
|
1,031 |
|
|
35 |
|
|
5,703 |
|
Adjusted EBITDA |
85 |
|
|
(192 |
) |
|
(1,939 |
) |
|
703 |
|
Non-IFRS financial measures should be considered
together with other data prepared in accordance with IFRS to enable
investors to evaluate the Company’s operating results, underlying
performance and prospects in a manner similar to EnWave’s
management. Accordingly, these non-IFRS financial measures are
intended to provide additional information and should not be
considered in isolation or as a substitute for measures of
performance prepared in accordance with IFRS. For more information,
please refer to the Non-IFRS Financial Measures section in the
Company’s MD&A available on SEDAR+ www.sedarplus.ca.
About EnWave EnWave is a global
leader in the innovation and application of vacuum microwave
dehydration. From its headquarters in Delta, BC, EnWave has
developed a robust intellectual property portfolio, perfected its
Radiant Energy Vacuum (REV™) technology, and transformed an
innovative idea into a proven, consistent, and scalable drying
solution for the food, pharmaceutical and cannabis industries that
vastly outperforms traditional drying methods in efficiency,
capacity, product quality, and cost.
With more than fifty royalty-generating partners
spanning twenty-three countries and five continents, EnWave’s
licensed partners are creating profitable, never-before-seen snacks
and ingredients, improving the quality and consistency of their
existing offerings, running leaner and getting to market faster
with the company’s patented technology, licensed machinery, and
expert guidance.
EnWave’s strategy is to sign royalty-bearing
commercial licenses with food producers who want to dry better,
faster and more economical than freeze drying, rack drying and air
drying, and enjoy the following benefits of producing exciting new
products, reaching optimal moisture levels up to seven times
faster, and improve product taste, texture, color and nutritional
value.
Learn more at EnWave.net.
EnWave CorporationMr. Brent
Charleton, CFAPresident and CEO
For further information:
Brent Charleton, CFA, President and CEO at +1 (778)
378-9616E-mail: bcharleton@enwave.net
Dylan Murray, CPA, CA, CFO at +1 (778) 870-0729E-mail:
dmurray@enwave.net
Safe Harbour for Forward-Looking Information
Statements: This press release may contain forward-looking
information based on management's expectations, estimates and
projections. All statements that address expectations or
projections about the future, including statements about the
Company's strategy for growth, product development, market
position, expected expenditures, and the expected synergies
following the closing are forward-looking statements. All
third-party claims referred to in this release are not guaranteed
to be accurate. All third-party references to market information in
this release are not guaranteed to be accurate as the Company did
not conduct the original primary research. These statements are not
a guarantee of future performance and involve a number of risks,
uncertainties and assumptions. Although the Company has attempted
to identify important factors that could cause actual results to
differ materially, there may be other factors that cause results
not to be as anticipated, estimated or intended. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
EnWave (TSXV:ENW)
Historical Stock Chart
From Oct 2024 to Nov 2024
EnWave (TSXV:ENW)
Historical Stock Chart
From Nov 2023 to Nov 2024